New hope for Tough-to-Treat lymphoma: adding a Brain-Penetrating drug to standard therapy
NCT ID NCT07371923
Summary
This study is testing whether adding a drug called zanubrutinib to standard chemotherapy can better control a fast-growing type of blood cancer called diffuse large B-cell lymphoma (DLBCL) in patients with high-risk features. It will enroll 50 newly diagnosed patients whose cancer is more likely to relapse or spread to the brain. The main goal is to see if this combination leads to more patients achieving complete remission and living longer without their cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.